Cosmos Health (NASDAQ: COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, has begun the application process to dual list its shares on Upstream. A trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, Cosmos anticipates that the dual listing will provide the company with access to a global, digital-first investor base, enabling investors to trade with USDC digital currency as well as credit, debit, PayPal and USD; the move should increase the company’s liquidity, enhance price discovery and globalize the opportunity for investment. Approval for Upstream listing is subject to acceptance by MERJ; however, as an existing NASDAQ issuer, Cosmos Health may qualify for an expedited listing process. “Our application process to Upstream is yet another avenue we are exploring, in order to increase the liquidity of our stock by attracting international investors, and ultimately increasing shareholder value,” said Cosmos Health CEO Greg Siokas in the press release. “Given the global and innovative nature of our brands and products, it is important that we reach out to a global audience of investors who are not bound by geography or currency parameters, and Upstream is an important medium in that endeavor.”

To view the full press release, visit https://ibn.fm/mzjzy

About Cosmos Health Inc.  

Cosmos Health is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products: Sky Premium Life and Mediterranation. Additionally, the company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and United Kingdom serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. For more information about this company, visit www.CosmosHoldings.com and www.SkyPremiumLife.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.